Han Yuting, Bian Zhiying, Zhao Jiatong, Xiao Haiying, Wang Hongyu, Gao Fei, Shi Weikai, Liu JinJin, Xu Jingdong, Xu Chun
Department of Endocrinology, The Third Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
The Third Clinical Medical College, Jinzhou Medical University, Jinzhou, 121001, China.
Eur J Med Res. 2025 Aug 11;30(1):731. doi: 10.1186/s40001-025-03000-9.
The gut-liver axis is particularly vulnerable, and the alterations in gut microbiota composition have been linked to post-transplant complications. Liver transplantation is a life-saving procedure for patients with end-stage liver disease, but post-transplant complications are common and can significantly impact long-term outcomes. Tacrolimus is a widely used immunosuppressive agent in liver transplantation, primarily aimed at preventing graft rejection and promoting long-term graft survival. However, its effects on gut microbiota and the subsequent metabolic consequences remain underexplored. In this review, we will synthesize the latest findings on the effects of tacrolimus on gut microbiota in liver transplant patients and discuss how these changes may contribute to the development of diabetes and insulin resistance. By elucidating the interplay between tacrolimus, gut microbiota, and metabolic health, we aim to provide insights into potential therapeutic strategies for improving post-transplant outcomes.
肠-肝轴特别脆弱，肠道微生物群组成的改变与移植后并发症有关。肝移植是终末期肝病患者的一种挽救生命的手术，但移植后并发症很常见，并且会显著影响长期预后。他克莫司是肝移植中广泛使用的免疫抑制剂，主要用于预防移植物排斥反应并促进移植物长期存活。然而，其对肠道微生物群的影响以及随后的代谢后果仍未得到充分研究。在本综述中，我们将综合关于他克莫司对肝移植患者肠道微生物群影响的最新研究结果，并讨论这些变化如何可能导致糖尿病和胰岛素抵抗的发生。通过阐明他克莫司、肠道微生物群和代谢健康之间的相互作用，我们旨在为改善移植后预后的潜在治疗策略提供见解。
